Destiny Pharma announces that it has conditionally raised total gross proceeds of approximately £0.87m through the Open Offer which was announced on 9 November 2020. This is in addition to the £9.5m raised in the Placing to support the acquisition of NTCD-M3.
Please press on link below for press release